Remestemcel-L-rknd for Steroid-Refractory Acute Graft-vs-Host Disease in Pediatric Patients
Upendra Mahat, Donna Przepiorka, Lola A. Fashoyin‐Aje
Abstract
This JAMA Insights discusses the FDA approval of remestemcel-L-rknd to treat graft-vs-host disease in children and provides regulatory considerations for this approval.
Topics & Concepts
MedicineHost (biology)Refractory (planetary science)Graft-versus-host diseaseDiseaseIntensive care medicineSurgeryInternal medicineBiologyAstrobiologyEcologyPhysicsHematopoietic Stem Cell TransplantationCAR-T cell therapy researchRenal Transplantation Outcomes and Treatments